Mona Ashiya - 27 Jul 2026 Form 3 Insider Report for Yarrow Bioscience, Inc. (VYNE)

Reporting relationship: Director
Issuer ticker: VYNE
Reported as of: 27 Jul 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 29 Jul 2026, 21:21:56 UTC
Prior SEC filing: 15 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Tyler Zeronda, as attorney-in-fact for Mona Ashiya

Key filing fact

Mona Ashiya filed Form 3 for Yarrow Bioscience, Inc. (VYNE) on 29 Jul 2026.

Key facts

This page summarizes Mona Ashiya's Form 3 filing for Yarrow Bioscience, Inc. (VYNE).
0 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 29 Jul 2026, 21:21.

Change

Previous filing in this sequence was filed on 15 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001794070 Primary reporting owner

Ashiya Mona

Relationship: Director
Address: C/O YARROW BIOSCIENCE, INC., 470 JAMES STREET, SUITE 007, NEW HAVEN
Signature: /s/ Tyler Zeronda, as attorney-in-fact for Mona Ashiya
Signature date: 29 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VYNE holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 233,019
Date: 27 Jul 2026
Ownership: See footnote
Footnotes: F1, F2, F3, F5

VYNE holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 33,287
Date: 27 Jul 2026
Ownership: See footnote
Footnotes: F1, F2, F4, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VYNE holding Derivative

Pre-Funded Warrants (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 27 Jul 2026
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 4,084,827
Exercise price: $0.000100
Footnotes: F3, F5, F6

VYNE holding Derivative

Pre-Funded Warrants (right to buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 27 Jul 2026
Ownership: See footnote
Underlying class: Common Stock
Underlying amount: 583,545
Exercise price: $0.000100
Footnotes: F4, F5, F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

Effective as of July 27, 2026 (the "Effective Time"), a wholly owned subsidiary of VYNE Therapeutics Inc. ("VYNE") merged with and into Yarrow Bioscience, Inc. ("Yarrow") with Yarrow continuing as a wholly owned subsidiary of VYNE and the surviving corporation of the merger (the "Merger") under the name "Yarrow Bioscience Operating Company Corp." In connection with the completion of the Merger, VYNE changed its name to "Yarrow Bioscience, Inc." (hereinafter, the "Issuer").

Footnote F2

Represents the number of shares of common stock, par value $0.0001, of the Issuer ("Issuer Common Stock") received by the entities listed below in the Merger in exchange for the shares of common stock of Yarrow ("Yarrow Common Stock") held by the entities listed below prior to the Merger. Each share of Yarrow Common Stock held at the Effective Time was exchanged for 0.7171 shares of Issuer Common Stock.

Footnote F3

These securities are held of record by OrbiMed Private Investments X, LP ("OPI X"). OrbiMed Capital GP X, LP ("GP X LP") is the general partner of OPI X. OrbiMed Capital GP X LLC ("GP X LLC") is the general partner of GP X LP. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP X LLC. By virtue of such relationships, GP X, LP, GP X LLC and OrbiMed Advisors may be deemed to have voting and investment power with respect to the shares held by OPI X. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI X.

Footnote F4

These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis Master Fund"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to shares held by Genesis Master Fund. OrbiMed Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund.

Footnote F5

Each of the Reporting Person, OrbiMed Advisors, GP X LLC and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a 1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Person, OrbiMed Advisors, GP X LLC or Genesis GP is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

Footnote F6

The Pre-Funded Warrants are exercisable at any time after the date of issuance, subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full.

SEC remarks

Exhibit 24 - Power of Attorney